Literature DB >> 31617074

Clinical significance of a pvrl 4 encoded gene Nectin-4 in metastasis and angiogenesis for tumor relapse.

Chinmayee Sethy1, Kunal Goutam2, Deepika Nayak1, Rajalaxmi Pradhan1, Sefinew Molla1, Subhajit Chatterjee1, Niranjan Rout3, Michael D Wyatt4, Satya Narayan5, Chanakya Nath Kundu6.   

Abstract

PURPOSE: In the present study, we have systematically examined the clinical significance of Nectin-4 (encoded by the PVRL-4 gene), a marker for breast cancer stem cells (CSCs), in cancer metastasis and angiogenesis using a variety of human specimens, including invasive duct carcinoma (IDC) with multiple grades, several types of primary tumors to local and distant relapses, lymph node metastases and circulating tumor cells (CTCs).
METHODS: Nectin-4 was overexpressed in more than 92% of samples with 65.2% Nectin-4-positive cells. The level of expression was increased with increasing tumor grade (GI-III) and size (T1-4) of IDC specimens.
RESULTS: More induction of Nectin-4 was noted in relapsed samples from a variety of tumors (colon, tongue, liver, kidney, ovary, buccal mucosa) in comparison to primary tumors, while paired adjacent normal tissues do not express any Nectin-4. A high expression of Nectin-4 along with other representative markers in CTCs and lymph node metastasis was also observed in cancer specimens. An increased level of Nectin-4 along with representative metastatic (CD-44, Sca1, ALDH1, Nanog) and angiogenic (Ang-I, Ang-II, VEGF) markers were noted in metastatic tumors (local and distant) in comparison to primary tumors that were correlated with different grades of tumor progression. In addition, greater expression of Nectin-4 was observed in secondary tumors (distant metastasis, e.g., breast to liver or stomach to gall bladder) in comparison to primary tumors.
CONCLUSION: Our study demonstrated a significant correlation between Nectin-4 expression and tumor grade as well as stages (p < 0.001), suggesting its association with tumor progression. Nectin-4 was overexpressed at all stages of metastasis and angiogenesis, thus appearing to play a major role in tumor relapse through the PI3K-Akt-NFκβ pathway.

Entities:  

Keywords:  Angiogenesis; Cancer relapse; Circulating tumor cells; Metastasis; Nectin-4

Mesh:

Substances:

Year:  2019        PMID: 31617074     DOI: 10.1007/s00432-019-03055-2

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  47 in total

Review 1.  Nectin and afadin: novel organizers of intercellular junctions.

Authors:  Yoshimi Takai; Hiroyuki Nakanishi
Journal:  J Cell Sci       Date:  2003-01-01       Impact factor: 5.285

2.  EMT and MET in metastasis: where are the cancer stem cells?

Authors:  Thomas Brabletz
Journal:  Cancer Cell       Date:  2012-12-11       Impact factor: 31.743

Review 3.  Prognosis and breast cancer. Recognition of lethal and favorable prognostic types.

Authors:  D L Page
Journal:  Am J Surg Pathol       Date:  1991-04       Impact factor: 6.394

4.  Nectin-4 is a breast cancer stem cell marker that induces WNT/β-catenin signaling via Pi3k/Akt axis.

Authors:  Sumit Siddharth; Kunal Goutam; Sarita Das; Anmada Nayak; Deepika Nayak; Chinmayee Sethy; Michael D Wyatt; Chanakya Nath Kundu
Journal:  Int J Biochem Cell Biol       Date:  2017-06-07       Impact factor: 5.085

5.  The significance of Survivin and Nectin-4 expression in the prognosis of breast carcinoma.

Authors:  Anna Maria Athanassiadou; Efstratios Patsouris; Angelos Tsipis; Maria Gonidi; Pauline Athanassiadou
Journal:  Folia Histochem Cytobiol       Date:  2011       Impact factor: 1.698

Review 6.  The VEGF pathway in cancer and disease: responses, resistance, and the path forward.

Authors:  Mark W Kieran; Raghu Kalluri; Yoon-Jae Cho
Journal:  Cold Spring Harb Perspect Med       Date:  2012-12-01       Impact factor: 6.915

Review 7.  Concise Review: Pancreatic Cancer and Bone Marrow-Derived Stem Cells.

Authors:  Wojciech Błogowski; Tomasz Bodnarczuk; Teresa Starzyńska
Journal:  Stem Cells Transl Med       Date:  2016-05-23       Impact factor: 6.940

8.  The expression of Nectin-4 on the surface of ovarian cancer cells alters their ability to adhere, migrate, aggregate, and proliferate.

Authors:  Kristin L M Boylan; Petra C Buchanan; Rory D Manion; Dip M Shukla; Kelly Braumberger; Cody Bruggemeyer; Amy P N Skubitz
Journal:  Oncotarget       Date:  2017-02-07

9.  Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients.

Authors:  Bahriye Aktas; Mitra Tewes; Tanja Fehm; Siegfried Hauch; Rainer Kimmig; Sabine Kasimir-Bauer
Journal:  Breast Cancer Res       Date:  2009-07-09       Impact factor: 6.466

10.  In vitro and in vivo inhibition of breast cancer cell growth by targeting the Hedgehog/GLI pathway with SMO (GDC-0449) or GLI (GANT-61) inhibitors.

Authors:  Monica Benvenuto; Laura Masuelli; Enrico De Smaele; Massimo Fantini; Rosanna Mattera; Danilo Cucchi; Elena Bonanno; Enrica Di Stefano; Giovanni Vanni Frajese; Augusto Orlandi; Isabella Screpanti; Alberto Gulino; Andrea Modesti; Roberto Bei
Journal:  Oncotarget       Date:  2016-02-23
View more
  6 in total

Review 1.  Nectin-4: a Novel Therapeutic Target for Skin Cancers.

Authors:  Hiroki Hashimoto; Yuka Tanaka; Maho Murata; Takamichi Ito
Journal:  Curr Treat Options Oncol       Date:  2022-03-21

Review 2.  Comparative Cancer Cell Signaling in Muscle-Invasive Urothelial Carcinoma of the Bladder in Dogs and Humans.

Authors:  Maria Malvina Tsamouri; Thomas M Steele; Maria Mudryj; Michael S Kent; Paramita M Ghosh
Journal:  Biomedicines       Date:  2021-10-14

3.  Nectin cell adhesion molecule 4 regulates angiogenesis through Src signaling and serves as a novel therapeutic target in angiosarcoma.

Authors:  Yuka Tanaka; Maho Murata; Keiko Tanegashima; Yoshinao Oda; Takamichi Ito
Journal:  Sci Rep       Date:  2022-03-07       Impact factor: 4.379

4.  High expression of nectin-1 indicates a poor prognosis and promotes metastasis in hepatocellular carcinoma.

Authors:  Xuequan Wang; Ziming Xing; Huazhong Chen; Haihua Yang; Qiupeng Wang; Tongjing Xing
Journal:  Front Oncol       Date:  2022-08-18       Impact factor: 5.738

Review 5.  Targeting nectin-4 by antibody-drug conjugates for the treatment of urothelial carcinoma.

Authors:  Jeffrey L Wong; Jonathan E Rosenberg
Journal:  Expert Opin Biol Ther       Date:  2021-05-24       Impact factor: 5.589

Review 6.  Differences of Angiogenesis Factors in Tumor and Diabetes Mellitus.

Authors:  Shidong Tan; Guangyao Zang; Ying Wang; Zhen Sun; Yalan Li; Cheng Lu; Zhongqun Wang
Journal:  Diabetes Metab Syndr Obes       Date:  2021-07-24       Impact factor: 3.168

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.